Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice

Journal of Clinical Investigation

Volumn 113, Issue 1, 2004, Pages 96-105

  Yakar, Shoshana ^a   Setser, Jennifer ^a   Zhao, Hong ^a   Stannard, Bethel ^a   Haluzik, Martin ^a   Glatt, Vaida ^b   Bouxsein, Mary L ^b   Kopchick, John J ^c   LeRoith, Derek ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; GROWTH HORMONE; INSULIN; SOMATOMEDIN C; TRIACYLGLYCEROL; SOMATOMEDIN;

ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; GROWTH HORMONE RELEASE; HORMONE ACTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSGENE; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; ORGAN SIZE; PHYSIOLOGY; REFERENCE VALUE; SECRETION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; GLUCOSE CLAMP TECHNIQUE; GROWTH HORMONE; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; ORGAN SIZE; REFERENCE VALUES; SOMATOMEDINS;

EID: 1542466784     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200417763     Document Type: Article

References (69)

1. Houssay, B.A. 1936. The hypophysis and metabolism. N. Engl. J. Med. 214:961.
2. Moller, N., et al. 1991. Effects of growth hormone on glucose metabolism. Horm. Res. 36(Suppl 1):32-35.
3. Davidson, M.B. 1987. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr. Rev. 8:115-131.
4. Beauville, M., et al. 1992. Effect of long-term rhGH administration in GH-deficient adults on far cell epinephrine response. Am. J. Physiol. 263:E467-E472.
5. Kamel, A., Norgren, S., Elimam, A., Danielsson, P., and Marcus, C. 2000. Effects of growth hormone treatment in obese prepubertal boys. J. Clin. Endocrinol. Metab. 85:1412-1419.
6. Dominici, F.P., Arosregui Diaz, G., Bartke, A., Kopchick, J.J., and Turyn, D. 2000. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. Endocrinol. 166:579-590.
7. Argetsinger, L.S., et al. 1995. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J. Biol. Chem. 270:14685-14692.
8. Argersinger, L.S., Norstedt, G., Billestrup, N., White, M.F., and Carter-Su, C. 1996. Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling. J. Biol. Chem. 271:29415-29421.
9. Thirone, A.C., Carvalho, C.R., and Saad, M.J. 1999. Growth hormone stimulates the tyrosine kinase activity of JAK2 and induces tyrosine phosphorylation of insulin receptor substrates and Shc in rat tissues. Endocrinology. 140:55-62.
10. VanderKuur, J., Allevaro, G., Billestrup, N., Norstedt, G., and Carter-Su, C. 1995. Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2. J. Biol. Chem. 270:7587-7593.
11. Vanderkuur, J.A., et al. 1997. Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology. 138:4301-4307.
12. Kilgour, E., Gout, I., and Anderson, N.G. 1996. Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen activated protein kinase and p70s6k pathways. Biochem. J. 315:517-522.
13. Adams, T.E., et al. 1998. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273:1285-1287.
14. Mooney, R.A., et al. 2001. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J. Biol. Chem. 276:25889-25893.
15. Peraldi, P., Filloux, C., Emanuelli, B., Hilton, D.J., and Van Obberghen, E. 2001. Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through Janus-activated kinase. J. Biol. Chem. 276:24614-24620.
16. Dey, B.R., Furlanetto, R.W., and Nissley, P. 2000. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-1 receptor. Biochem. Biophys. Res. Commun. 278:38-43.
17. Emanuelli, B., et al. 2000. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275:15985-15991.
18. Rui, L., Yuan, M., Frantz, D., Shoelson, S., and White, M.F. 2002. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277:42394-42398.
19. Kawazoe, Y., et al. 2001. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS 1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J. Exp. Med. 193:263-269.
20. Krebs, D.L., et al. 2002. SOCS 6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol. Cell. Biol. 22:4567-4578.
21. Yakar, S., et al. 2001. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes. 50:1110-1118.
22. Chen, W.Y., White, M.E., Wagner, T.E., and Kopchick, J.J. 1991. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129:1402-1408.
23. Yakar, S., et al. 1999. Normal growth and development in the absence of hepatic insulin like growth factor 1. Proc. Natl. Acad. Sci. U. S. A. 96:7324-7329.
24. Burant, C.F., et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-2908.
25. Gavrilova, O., et al. 1999. Torpor in mice is induced by both leptin dependent and independent mechanisms. Proc. Natl. Acad. Sci. U. S. A. 96:14623-14628.
26. Kim, J.K., et al. 2000. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest. 105:1791-1797.
27. MacLeod, J.N., and Shapiro, B.H. 1988. Repetitive blood sampling in unrestrained and unstressed mice using a chronic indwelling right atrial catheterization apparatus. Lab. Anim. Sci. 38:603-608.
28. Colombo, C., et al. 2003. Opposite effects of background genotype on muscle and liver insulin sensitivity of lipoatrophic mice. Role of triglyceride clearance. J. Biol. Chem. 278:3992-3999.
29. Kieffer, T.J., Heller, R.S., and Habener, J.F. 1996. Leptin receptors expressed on pancreatic beta-cells. Biochem. Biophys. Res. Commun. 224:522-527.
30. Ceddia, R.B., William, W.N., Jr., Carpinelli, A.R., and Curi, R. 1999. Modulation of insulin secretion by leptin. Gen. Pharmacol. 32:233-237.
31. Tanizawa, Y., et al. 1997. Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells. Endocrinology. 138:4513-4516.
32. Shimomura, I., et al. 2000. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell. 6:77-86.
33. Bartke, A., et al. 1999. Effects of growth hormone overexpression and growth hormone resistance on neuroendocrine and reproductive functions in transgenic and knock-out mice. Proc. Soc. Exp. Biol. Med. 222:113-123.
34. Lippe, BM., Kaplan, S.A., Golden, M.P., Hendricks, S.A., and Scott, M.L. 1981. Carbohydrate tolerance and insulin receptor binding in children with hypopituitarism: response after acute and chronic human growth hormone administration. J. Clin. Endocrinol. Metab. 53:507-513.
35. Merimee, T.J., Felig, P., Marliss, E., Fineberg, S.E., and Cahill, G.G., Jr. 1971. Glucose and lipid homeostasis in the absence of human growth hormone. J. Clin. Invest. 50:574-582.
36. Grunt, J.A., Crigler, J.F., Jr., Slone, D., and Soeldner, J.S. 1967. Changes in serum insulin, blood sugar, and free fatty acid levels four hours after administration of human growth hormone to fasting children with short stature. Yale J. Biol. Med. 40:68-74.
37. Costin, G., Kogut, M.D., and Frasier, S.D. 1972. Effect of low dose human growth hormone on carbohydrate metabolism in children with hypopituitarism. J. Pediatr. 80:796-803.
38. Bougneres, P.F., Artavia-Loria, E., Fetre, P., Chaussain, J.L., and Job, J.C. 1985. Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood. J. Clin. Endocrinol. Metab. 61:1152-1157.
39. Daugaard, J.R., Laustsen, J.L., Hansen, B.S., and Richter, E.A. 1999. Insulin action in growth hormone-deficient and age-matched control rats: effect of growth hormone treatment. J. Endocrinol. 160:127-135.
40. Altszuler, N. 1974. Actions of growth hormone and carbohydrate metabolism. American Physiological Society. Washington, DC, USA 233-252.
41. De Bodo, R.C., and Altszuler, N. 1958. Insulin hypersensitivity and physiological insulin antagonists. Physiol. Rev. 38:389-445.
42. Sonksen, P.H., et al. 1967. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J. Clin. Endocrinol. Metab. 27:1418-1430.
43. Liebetmeister, H., et al. 1968. Serum insulin in acromegaly. Comparative investigations by a radio-immunological method and the biological methods using adipose and muscle tissue. Diabetologia. 4:195-202.
44. Elkeles, R.S., Wright, A.D., Lowy, C., and Fraser, T.R. 1969. Serum-insulin in acromegaly. Lancet 2:615-618.
45. Akerblom, H.K., Newman, P.R., Meakin, J.W., Martin, J.M., and Simpson, W.J. 1969. Insulin and growth hormone responses to glucose loading in treated acromegalics. Diabetologia. 5:183-187.
46. Trimble, E.R., Atkinson, A.B., Buchanan, K.D., and Hadden, D.R. 1980. Plasma glucagon and insulin concentrations in acromegaly. J. Clin. Endocrinol. Metab. 51:626-631.
47. Sato, K., Takamatsu, K., and Hashimoto, K. 1995. Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocr. J. 42:739-745.
48. Hansen, I., et al. 1986. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am. J. Physiol. 250:E269-E273.
49. Foss, M.C., et al. 1991. Peripheral glucose metabolism in acromegaly. J. Clin. Endocrinol. Metab. 72:1048-1053.
50. Ho, K.K., Jenkins, A.B., Furler, S.M., Borkman, M., and Chisholm, D.J. 1992. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol. (Oxf). 36:271-279.
51. van der Lely, A.J., et al. 2001. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 358:1754-1759.
52. Rose, D.R., and Clemmons, D.R. 2002. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm. IGF Res. 12:418-424.
53. O'Connell, T., and Clemmons, D.R. 2002. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J. Clin. Endocrinol. Metab. 87:4356-4360.
54. Cartel, A.L., and Allen, D.B. 2000. Effects of growth hormone on adipose tissue. J. Pediatr. Endocrinol. Metab. 13(Suppl 2):1003-1009.
55. Nam, S.Y., and Marcus, C. 2000. Growth hormone and adipocyte function in obesity. Horm. Res. 53(Suppl 1):87-97.
56. Richelsen, B., et al. 1994. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. 266:E211-E216.
57. Goodman, H.M. 1968. Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue. Ann. N. Y. Acad. Sci. 148:419-440.
58. Carroll, P.V., et al. 1998. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83:382-395.
59. Salomon, F., Cuneo, R.C., Hesp, R., and Sonksen, P.H. 1989. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321:1797-1803.
60. Boni-Schnetzler, M., Gosteli-Peter, M.A., Moritz, W., Froesch, E.R., and Zapf, J. 1996. Reduced ob mRNA in hypophysectomised rats is not restored by growth hormone (GH), but further suppressed by exogenously administered insulin-like growth factor (IGF). J. Biochem. Biophys. Res. Commun. 225:296-301.
61. Boni-Schnetzler, M., Hauri, C., and Zapf, J. 1999. Leptin is suppressed during infusion of recombinant human insulin-like growth factor 1 (rhIGF1) in normal rats. Diabetologia. 42:160-166.
62. Berger, J., and Moller, D.E. 2002. The mechanisms of action of PPARs. Annu. Rev. Med 53:409-435.
63. Reddy, J.K., and Hashimoto, T. 2001. Peroxisomal beta-oxidation and peroxisome proliferated-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21:193-230.
64. Johnson, E.F., Palmer, C.N., Griffin, K.J., and Hsu, M.H. 1996. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J. 10:1241-1248.
65. Aoyama, T., et al. 1998. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 273:5678-5684.
66. Moody, D.E., Loury, D.N., and Hammock, B.D. 1985. Epoxide metabolism in the liver of mice treated with clofibrate (ethyl-alpha-(p-chlorophenoxyisobutyrate], a peroxisome proliferator. Toxicol. Appl. Pharmacol. 78:351-362.
67. Carlsson, L., Linden, D., Jalouli, M., and Oscarsson, J. 2001. Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPARalpha in rat liver. Am. J. Physiol. Endocrinol. Metab. 281:E772-E781.
68. Chinetti, G., et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7:53-58.
69. Brady, P.S., Marine, K.A., Brady, L.J., and Ramsay, R.R. 1989. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochem. J. 260:93-100.